Blog review: Dell’s IR blog
November 9, 2007
As I’m sure you know by now, Dell launched the first Investor Relations blog just over a week ago, to quite a bit of comment around the patch, and they’ve got a couple of posts up now.
This blog is a really very interesting addition to the IR site, and Dell are typically brave to be the first (though I suppose someone has to!). I’m sure it won’t be long before other companies join them … Read more
If you're new here, and have enjoyed what you've read, you may want to subscribe to my RSS feed. Thanks for visiting!
Best Practices Review: Chemoil
November 7, 2007
Time for another quick review: 15 minutes to assess Chemoil’s corporate website.
There is much to be commended in this site. Chemoil includes a number of items that many other companies fail to include, such as: video, podcast, webcast, a glossary, FAQs, third party comment, a sitemap, biographies of both board members and management, a dedicated shareholder page, details on insider trades and a good explanation of their business and strategy - as well as a great deal of other information.
However, the site overall does have a few flaws, and I have some suggestions for improvement. Read more
8 ways of charting your share price (or not)
November 5, 2007
Ever wondered what everyone else was using to chart their share price? Here are eight different ways of charting the share price.
Many if not most FTSE 100 companies now provide interactive share charting facilities, so that visitors can see the trend over the last day, week, month … or whatever period interests them.
Some companies provide the option to compare the performance of their stock with indices and sector - perhaps the FTSE or equivalent, or a set of related companies.
A subset of these companies make it easy to compare their own performance with that of their direct competition. For example, Roche make it easy to see how they are doing compared to Bayer, or Pfizer, GSK or AstraZeneca (among several others).
A very few companies make it easy to compare their performance against apparently any listed company. Read more